Impact of Ammonia Supply Advisory on India's Pharmaceutical Industry

India's pharmaceutical industry is facing a potential challenge due to an advisory that restricts the sale of surplus ammonia to the fertilizer sector. This advisory has raised significant concerns among drug manufacturers who depend on ammonia for producing medicines and active pharmaceutical ingredients (APIs).

Key Points of the Advisory

• Directive Issued: The department of fertilizers has issued an advisory that mandates urea manufacturing units to sell surplus ammonia exclusively for fertilizer production. 
• Sales Priority: Priority is given to phosphorus and potassium (P&K) and nitrogen, phosphorus, potassium (NPK) manufacturers of subsidized fertilizers, ensuring they receive ammonia at reasonable prices. 
• Compliance with Regulations: The advisory aligns with a gazette notification by the ministry of petroleum and natural gas stipulating that natural gas supplied to fertilizer plants must be used solely for fertilizer production. 

Concerns Raised by the Pharmaceutical Sector

• Potential Disruption: Industry executives express that if the directive is implemented, it could disrupt domestic pharmaceutical production, cause medicine shortages, and impact export commitments. 
• Dependency on Ammonia: The pharmaceutical sector relies heavily on ammonia for synthesizing APIs, intermediates, and formulations. 
• Export Concerns: Prolonged shortages may lead to production cuts, delays in fulfilling orders, and strained relationships with international buyers. 

Response from Pharmaceutical Industry

• Pharmexcil's Stand: Namit Joshi, chairman of Pharmexcil, highlights the potential impact on pharma, stating the need for clarification on the advisory. 
• Industry Actions: Pharmexcil plans to take up the matter with the government to address the concerns.